CADL vs. ARDX, ELVN, VERV, NAGE, DYN, CDTX, COLL, BGM, PHVS, and NRIX
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), Collegium Pharmaceutical (COLL), BGM Group (BGM), Pharvaris (PHVS), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.
Candel Therapeutics vs. Its Competitors
Ardelyx (NASDAQ:ARDX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.
In the previous week, Candel Therapeutics had 4 more articles in the media than Ardelyx. MarketBeat recorded 11 mentions for Candel Therapeutics and 7 mentions for Ardelyx. Candel Therapeutics' average media sentiment score of 1.28 beat Ardelyx's score of 0.75 indicating that Candel Therapeutics is being referred to more favorably in the news media.
58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by insiders. Comparatively, 16.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Candel Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -14.86%. Ardelyx's return on equity of -34.45% beat Candel Therapeutics' return on equity.
Ardelyx has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.91, suggesting that its share price is 191% less volatile than the S&P 500.
Ardelyx presently has a consensus price target of $10.89, suggesting a potential upside of 136.20%. Candel Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 242.15%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Ardelyx.
Ardelyx has higher revenue and earnings than Candel Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Ardelyx beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CADL) was last updated on 7/15/2025 by MarketBeat.com Staff
Free CADL Stock Alerts